Bjørn Tore Gjertsen

Research interests

Publications

• Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

  Cancer Discovery · 2021 · https://doi.org/10.1158/2159-8290.cd-21-0410

• Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

  The Lancet Haematology · 2019 · https://doi.org/10.1016/s2352-3026(19)30110-3

• Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia

  Haematologica · 2019 · https://doi.org/10.3324/haematol.2018.214882

• Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

  Leukemia · 2018 · https://doi.org/10.1038/s41375-018-0210-1

• A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer

  Journal of Controlled Release · 2016 · https://doi.org/10.1016/j.jconrel.2016.10.007

• SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells

  Cell stem cell · 2014 · https://doi.org/10.1016/j.stem.2014.08.001

• Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia

  Cancer Discovery · 2013 · https://doi.org/10.1158/2159-8290.cd-13-0350

• Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

  Proceedings of the National Academy of Sciences · 2009 · https://doi.org/10.1073/pnas.0909333107

• Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells

  Cell · 2004 · https://doi.org/10.1016/j.cell.2004.06.028

• Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris

  The Lancet · 1991 · https://doi.org/10.1016/0140-6736(91)92157-w

Current projects

No projects listed.